Details of the Drug

General Information of Drug (ID: DM0FJIE)

Drug Name
Ontuxizumab
Synonyms Amatuximab
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 2 [1]
Merkel cell carcinoma 2C34 Phase 2 [1]
Soft tissue sarcoma 2B57 Phase 2 [2]
Colorectal cancer 2B91.Z Phase 1 [3]
Drug Type
Antibody
Cross-matching ID
DrugBank ID
DB16270
TTD ID
D0FK9H
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Endosialin (CD248) TTYJWT7 CD248_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Melanoma
ICD Disease Classification 2C30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Endosialin (CD248) DTT CD248 2.40E-173 2.18 3.53
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):380-8.